Roth Capital Cuts Earnings Estimates for Tenax Therapeutics

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Roth Capital dropped their FY2027 earnings estimates for Tenax Therapeutics in a note issued to investors on Wednesday, March 5th. Roth Capital analyst J. Aschoff now anticipates that the specialty pharmaceutical company will earn $1.74 per share for the year, down from their previous estimate of $1.82. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ FY2028 earnings at $2.94 EPS.

Tenax Therapeutics Price Performance

Tenax Therapeutics stock opened at $6.19 on Friday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The company’s 50-day moving average is $6.45 and its 200 day moving average is $5.16.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TENX. Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics during the 4th quarter worth approximately $84,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics during the third quarter worth $101,000. Geode Capital Management LLC boosted its stake in shares of Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 5,964 shares during the period. Millennium Management LLC bought a new position in shares of Tenax Therapeutics in the fourth quarter worth about $166,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics in the third quarter worth about $173,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.